SCHEMBL1833368

SCHEMBL1833368

Cn1c(-c2noc(N3CCN(C(=O)O)CC3)n2)nc2ccc(F)cc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 6/20 0.54
MAPT P10636 4/20 0.40
LMNA P02545 4/20 0.40
HTT P42858 2/20 0.40
NPC1 O15118 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ERG P11308 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FAAH O00519 1/20 0.37
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
RAB9A P51151 1/20 0.36
NAAA Q02083 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1831147 0.92 SMO (0.54) SMOMAPTLMNAHTTNPC1
SCHEMBL1830468 0.85 SMO (0.71) SMOMAPTLMNAHTTNPC1
Hydrochloric Acid SCHEMBL1831842 0.82 SMO (0.43) SMOCYP11B1CYP11B2POLB
Trifluoroacetic Acid SCHEMBL2158300 0.80 SMO (0.74) SMOMAPTLMNAHTTPOLB
Hydrochloric Acid SCHEMBL1837642 0.74 SMO (0.43) SMOMAPT
SCHEMBL2158212 0.72 CYP11B2 (0.46) CYP11B1CYP11B2
Trifluoroacetic Acid SCHEMBL1831949 0.70 SMO (0.57) SMOMAPTNPC1POLBKDM4E
SCHEMBL2158836 0.70 SMO (1.00) SMOERGSMN1; SMN2RAB9A
SCHEMBL1830934 0.67 SMO (0.56) SMOMAPTLMNAHTTNPC1
SCHEMBL1830874 0.67 SMO (0.74) SMOERG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183974-A1 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) 2011-07-28 US disclosed
EP-2318400-A1 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2011-05-11 EP disclosed
WO-2010013037-A1 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183974-A1 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS SHH, SMO, GLI1 SMO 2/4885MAPT 883/4885LMNA 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.